Michele M. Luchetti*, Devis Benfaremo and Armando Gabrielli Pages 989 - 1007 ( 19 )
Background: Biologic drugs, introduced in clinical practice almost twenty years ago, represent nowadays a prominent treatment option in patients with chronic inflammatory arthritis, such as Rheumatoid Arthritis, Psoriatic Arthritis and Spondyloarthritis, that include ankylosing spondylitis and non-radiographic axial spondyloarthritis.
Methods: Several compounds targeting different pathways have been marketed and approved for the treatment of inflammatory arthritis, with a significant impact on the clinical outcomes and the natural history of the diseases.
Results: There are currently seven classes of biologics that are available for the treatment of inflammatory arthritis, each inhibiting a different aspect of the immune-driven inflammatory pathway.
• Tumor Necrosis Factor (TNF) inhibitors (infliximab, adalimumab, etanercept, golimumab and certolizumab pegol);
• Interleukin-1 (IL-1) receptor antagonists (anakinra);
• Interleukin-6 (IL-6) inhibition (tocilizumab);
• Interleukin-12/23 (IL23) inhibition (ustekinumab);
• Interleukin-17 (IL-17) inhibition (secukinumab);
• B-cell inhibition (anti-CD20, rituximab);
• T-cell costimulation inhibition (anti-CTLA-4, abatacept).
Conclusion: In this review, we will focus on the role of biologic drugs in the treatment strategies for inflammatory arthritis.
Biologic drugs, TNF inhibitors, rheumatoid arthritis, spondyloarthritis, psoriatic arthritis, efficacy, safety.
Dipartimento Scienze Cliniche e Molecolari, Sezione di Clinica Medica, Universita Politecnica delle Marche, Ancona, Dipartimento Scienze Cliniche e Molecolari, Sezione di Clinica Medica, Universita Politecnica delle Marche, Ancona, Dipartimento Scienze Cliniche e Molecolari, Sezione di Clinica Medica, Universita Politecnica delle Marche, Ancona